Axogen, Inc. disclosed its preliminary unaudited financials for the fourth quarter and full-year 2025, highlighting significant growth in revenue.
The revenue growth is driven by strong performance across various product segments.
The company emphasized its strategic focus on high-potential accounts and the expansion of its surgical algorithm.
Gross margin is expected to exceed 74% for the fourth quarter and full-year 2025.
Revenue Growth
In Q4 2025, revenue is projected to increase by 21.3%, with a full-year growth of 20.2% compared to 2024.
BLA Approval
The FDA approval of Avance® as a biologic therapeutic option for peripheral nerve discontinuities opens new market opportunities.
Cash Position
The balance of cash, cash equivalents, and investments is anticipated to grow by $6.0 million from 2024.
- The robust revenue growth reflects Axogen's effective commercial strategy and operational execution.
- The BLA approval for Avance® broadens Axogen's footprint in the market for peripheral nerve repair therapies.
Axogen's positive performance in 2025, characterized by revenue growth and strategic milestones, sets a strong foundation for future success.